Navigation Links
Paragon Bioservices Awarded $4.99 Million U.S. Army Contract to Assist with Ebola Vaccine Development
Date:10/21/2010

BALTIMORE, Oct. 21 /PRNewswire/ -- Paragon Bioservices, a Baltimore-based CMO focused on the contract research, process development and manufacturing of biologics, announced today that it has been awarded a $4.99 million contract to assist the U.S. Army Medical Research Institute for Infectious Diseases (USAMRIID) in its vaccine development efforts.

The USAMRIID project involves process development and scale-up production of VLP-type vaccines against Ebola Zaire, Ebola Sudan, and Marburg viruses to support ongoing preclinical evaluation of efficacy, potency, and safety of these Filovirus vaccine candidates.  Utilizing their extensive VLP production and purification expertise, Paragon will develop a large-scale mammalian process suitable for future GMP manufacturing.

Ebola and Marburg viruses are a serious global health threat.  They cause hemorrhagic fever and have up to a 90 percent fatality rate in humans.  Currently, there are no vaccines or therapies available for these viruses.  They are commonly spread through blood and bodily fluids of infected patients who frequently succumb to hypovolemic shock.  Both viruses are potential agents of biological warfare or terrorism, since both are also infectious by aerosol.

Marco Chacon, Ph.D., CEO of Paragon Bioservices, commented, "As a scientist and a business man, it is extremely rewarding to be part of an effort that may improve public health, as well as enhance national preparedness.  Preventing the spread of Ebola and Marburg viruses is crucial to containing outbreaks and saving lives."

About Paragon BioservicesParagon Bioservices is a CMO focused on providing contract research, process development services and GMP manufacturing of biologics for Phase I/II clinical trials.  For more information about Paragon Bioservices, please visit www.paragonbioservices.com.

About USAMRIIDUSAMRIID, a division of the U.S. Army Medical Research and Materiel Command, plays a key role in both national defense and infectious disease research.  They are the lead medical research laboratory for the Department of Defense and the Biological Defense Research Program.  Their mission is essentially to conduct basic research on biological threats and to develop appropriate medical solutions—such as vaccines, drugs and diagnostics.Media Contacts:Tiberend Strategic Advisors, Inc.(212) 827-0020 Tamara Brighttbright@tiberendstrategicadvisors.comorClaire Sojdacsojda@tiberendstrategicadvisors.com
'/>"/>

SOURCE Paragon Bioservices
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Paragon Bioservices, Inc. Wins 2009 Lilly Global Supplier Award
2. ParagonRx Creates New Website Featuring REMS Help Center for Pharma
3. ParagonRx Files with FDA REMS Panel Interim Analysis for Opioid Drugs Study
4. ParagonRx Sponsors Webinar-on-Demand By DSEC on Role of Drug Safety Officers
5. Avid Bioservices Expands Capabilities With Installation of Innovative Thermo Scientific HyClone Single-Use Bioreactor Systems
6. Avid Bioservices Presents Data From Manufacturing Successes Achieved With Single-Use Bioreactor Systems
7. Avid Bioservices Expands Executive Team as it Prepares for Continued Growth
8. Advanced Life Sciences Awarded U.S. Department of Defense Biodefense Contract Valued at up to $3.8 Million
9. Dr. Yong Shi awarded NSF grant
10. eGenomics Awarded First U.S. Patent Covering Rapid DNA Sequencing Technology Platform to Control Hospital-Acquired Infections
11. Microchip Biotechnologies, Inc. Awarded Contract Under US Army Commercialization Pilot Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... LONDON , Feb. 9, 2016 /PRNewswire/ ... (PTP1B) Inhibitors-Pipeline Insights, 2016", report provides in ... their development activities around the Protein-Tyrosine Phosphatase ... the product profiles in various stages of ... Phase II, Phase III and Preregistration. Report ...
(Date:2/8/2016)... Should antibiotic bone cement products be used ... infection after standard total hip or knee replacement surgery? ... have been fielding a lot lately. "Antibiotic ... --> "Antibiotic Bone Cement: Fighting ... --> While there isn,t a simple answer, ECRI ...
(Date:2/8/2016)... , February 8, 2016 ... Oncology Private Limited, an innovation-driven oncology company developing ... and less toxic, today announced that chairman emeritus ... has invested in the company as part of ... round, joining existing investors Navam Capital and Aarin ...
(Date:2/8/2016)... ... 2016 , ... Thomas J. Todorow has joined the University ... Corporate Services and the Chief Financial Officer at The Children’s Hospital of Philadelphia ... Care Contracting, Supply Chain, and Investments. , Prior to joining CHOP and The ...
Breaking Biology Technology:
(Date:2/3/2016)... --> --> Fourth quarter ... up 1,187% compared with fourth quarter of 2014. Gross margin ... (loss: 30.0). Earnings per share increased to SEK 6.39 (loss: ... (neg: 74.7). , --> --> ... 2,900.5 M (233.6), up 1,142% compared with 2014. Gross margin ...
(Date:2/2/2016)... , Feb. 2, 2016  BioMEMS devices ... primarily focused on medical screening and diagnostic ... parameters. Wearable devices that facilitate and assure ... of movement are being bolstered through new ... biomedical signal acquisition coupled with wireless connectivity ...
(Date:2/2/2016)... RESTON, Va. , Feb. 2, 2016 /PRNewswire/ ... contract award from the U.S. Army Research Office ... extend the range and sensitivity of the company,s ... DoD,s Past Accounting Mission and, more generally, defense-related ... its DNA phenotyping capabilities (predicting appearance and ancestry ...
Breaking Biology News(10 mins):